Hypertension 2025 Scientific Sessions  /  My Top Clinical-Practice Changing Papers this Year  /  The Global Risk Consortium. Global effect of CV risk factors on lifetime estimates 2Saxena M, et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension
Logo

American Heart Association

  87
  0

Final ID:

The Global Risk Consortium. Global effect of CV risk factors on lifetime estimates 2Saxena M, et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension

  • Weir, Matthew  ( UNIVERSITY MARYLAND SCHOOL MED , Lutherville , Maryland , United States )
    • Author Disclosures:
    Matthew Weir: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Vera:Active (exists now) ; Consultant:Corcept:Active (exists now) ; Consultant:CSL Vifor:Active (exists now) ; Consultant:Mineralys:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Bayer:Active (exists now)
Meeting Info:

Hypertension 2025 Scientific Sessions

2025

Baltimore, Maryland

Session Info:

My Top Clinical-Practice Changing Papers this Year

Sunday, 09/07/2025 , 08:00AM - 08:45AM

Primary Care

More abstracts on this topic:
BPROAD Research Group. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease. Nephrol Dial Transplant

Townsend Raymond

Antihypertensive Medication Timing and Cardiovascular Events and Death The BedMed Randomized Clinical Trial.
irzepatide for the treatment of OSA and obesity

Voora Raven

More abstracts from these authors:
Aldosterone synthase inhibitors

Laffin Luke, Weir Matthew

Hypertension anxiety – When self-measurement goes wrong

Jamerson Kenneth, Weir Matthew

You have to be authorized to contact abstract author. Please, Login
Not Available